HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
Sample Articles
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
PRODUCTS
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1642
On December 22, 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir (Paxlovid – Pfizer) for oral treatment of mild to moderate COVID-19 in outpatients ≥12 years old who weigh at least 40 kg and are at high risk of progressing to severe disease, including hospitalization or death. Paxlovid was the first oral antiviral drug to be authorized in the US for treatment of COVID-19; Merck's oral antiviral drug molnupiravir was granted an...  read more...
More from issue 1642
Coming Soon
Drugs for Acute Otitis Media in Children
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
Difelikefalin (Korsuva) for Chronic Kidney Disease-Associated Pruritus
Recommend to Your Library  
Previous Issues
© 2022 The Medical Letter, Inc.